PE20251285A1 - Composiciones farmaceuticas de glp1 - Google Patents
Composiciones farmaceuticas de glp1Info
- Publication number
- PE20251285A1 PE20251285A1 PE2024002463A PE2024002463A PE20251285A1 PE 20251285 A1 PE20251285 A1 PE 20251285A1 PE 2024002463 A PE2024002463 A PE 2024002463A PE 2024002463 A PE2024002463 A PE 2024002463A PE 20251285 A1 PE20251285 A1 PE 20251285A1
- Authority
- PE
- Peru
- Prior art keywords
- fluoro
- glp1
- pharmaceutical compositions
- oxoimi
- methylindazol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se refiere a una composicion de capsula oral solida que pueden ser utiles para el tratamiento de la diabetes mellitus tipo 2 (DT2) y en el control de peso, que comprende una dispersion secada por pulverizacion (SDD) de 3-[(1S,2S)-1-[5-[(4S)-2,2-dimetiloxano-4-il]-2-[(4S)-2-(4-fluoro-3,5-dimetilfenil)-3-[3-(4-fluoro-1-metilindazol-5-il)-2-oxoimidazol-1-il]-4-metil-6,7-dihidro-4H-pirazolo[4,3-c]piridina-5-carbonil]indol-1-il]-2-metilciclopropilo]-4H-1,2,4-oxadiazol-5-ona, o una sal farmaceuticamente aceptable de esta; y un modificador de pH seleccionado de carbonato de calcio, carbonato de magnesio, bicarbonato de sodio, entre otros y una mezcla de estos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263340591P | 2022-05-11 | 2022-05-11 | |
| PCT/US2023/021637 WO2023220109A1 (en) | 2022-05-11 | 2023-05-10 | Glp1 pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20251285A1 true PE20251285A1 (es) | 2025-05-14 |
Family
ID=86732348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024002463A PE20251285A1 (es) | 2022-05-11 | 2023-05-10 | Composiciones farmaceuticas de glp1 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20250302809A1 (es) |
| EP (1) | EP4522129A1 (es) |
| JP (1) | JP7767651B2 (es) |
| KR (1) | KR20250002778A (es) |
| CN (1) | CN119173255A (es) |
| AR (1) | AR129296A1 (es) |
| AU (1) | AU2023269995A1 (es) |
| CA (1) | CA3253043A1 (es) |
| CL (1) | CL2024003392A1 (es) |
| CO (1) | CO2024015285A2 (es) |
| DO (1) | DOP2024000232A (es) |
| IL (1) | IL316629A (es) |
| MX (1) | MX2024013839A (es) |
| PE (1) | PE20251285A1 (es) |
| TW (2) | TW202508581A (es) |
| WO (1) | WO2023220109A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025057134A2 (en) | 2023-09-14 | 2025-03-20 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| TW202540124A (zh) * | 2023-11-21 | 2025-10-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 雜環類化合物、其製備方法及其在醫藥上的應用 |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002064132A2 (en) * | 2001-01-18 | 2002-08-22 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| US7115565B2 (en) * | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| CN101511184A (zh) * | 2006-09-08 | 2009-08-19 | 默克公司 | 用于口服给药cgrp拮抗剂的液体药物制剂 |
| JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| JP7461104B2 (ja) * | 2017-11-29 | 2024-04-03 | 中外製薬株式会社 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
| MA54395A (fr) | 2018-12-07 | 2022-03-16 | Neurocrine Biosciences Inc | Antagoniste du récepteur crf1, formulations pharmaceutiques et formes solides correspondantes pour le traitement de l'hyperplasie surrénalienne congénitale |
| US11884672B2 (en) | 2019-05-14 | 2024-01-30 | Vertex Pharmaceuticals Incorporated | Modulators of alpha-1 antitrypsin |
| AU2021341936A1 (en) | 2020-09-09 | 2023-05-25 | Crinetics Pharmaceuticals, Inc. | Formulations of a somatostatin modulator |
| WO2023220112A1 (en) | 2022-05-11 | 2023-11-16 | Eli Lilly And Company | Glp1 tablet compositions |
-
2023
- 2023-05-10 PE PE2024002463A patent/PE20251285A1/es unknown
- 2023-05-10 JP JP2024566219A patent/JP7767651B2/ja active Active
- 2023-05-10 US US18/864,210 patent/US20250302809A1/en active Pending
- 2023-05-10 IL IL316629A patent/IL316629A/en unknown
- 2023-05-10 KR KR1020247040462A patent/KR20250002778A/ko active Pending
- 2023-05-10 EP EP23729579.5A patent/EP4522129A1/en active Pending
- 2023-05-10 CA CA3253043A patent/CA3253043A1/en active Pending
- 2023-05-10 WO PCT/US2023/021637 patent/WO2023220109A1/en not_active Ceased
- 2023-05-10 AU AU2023269995A patent/AU2023269995A1/en active Pending
- 2023-05-10 CN CN202380039380.7A patent/CN119173255A/zh active Pending
- 2023-05-11 TW TW113144409A patent/TW202508581A/zh unknown
- 2023-05-11 TW TW112117510A patent/TWI867526B/zh active
- 2023-05-11 AR ARP230101165A patent/AR129296A1/es unknown
-
2024
- 2024-11-06 CL CL2024003392A patent/CL2024003392A1/es unknown
- 2024-11-08 MX MX2024013839A patent/MX2024013839A/es unknown
- 2024-11-08 CO CONC2024/0015285A patent/CO2024015285A2/es unknown
- 2024-11-11 DO DO2024000232A patent/DOP2024000232A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250002778A (ko) | 2025-01-07 |
| WO2023220109A1 (en) | 2023-11-16 |
| DOP2024000232A (es) | 2024-12-30 |
| CN119173255A (zh) | 2024-12-20 |
| AU2023269995A1 (en) | 2024-11-14 |
| JP7767651B2 (ja) | 2025-11-11 |
| TWI867526B (zh) | 2024-12-21 |
| CL2024003392A1 (es) | 2025-03-14 |
| EP4522129A1 (en) | 2025-03-19 |
| US20250302809A1 (en) | 2025-10-02 |
| CO2024015285A2 (es) | 2024-11-28 |
| JP2025515706A (ja) | 2025-05-20 |
| TW202410894A (zh) | 2024-03-16 |
| AR129296A1 (es) | 2024-08-07 |
| IL316629A (en) | 2024-12-01 |
| TW202508581A (zh) | 2025-03-01 |
| CA3253043A1 (en) | 2023-11-16 |
| MX2024013839A (es) | 2024-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20251285A1 (es) | Composiciones farmaceuticas de glp1 | |
| JP2023156479A (ja) | ジペプチジルペプチダーゼ１阻害剤としての（２ｓ）－ｎ－［（１ｓ）－１－シアノ－２－フェニルエチル］－１，４－オキサゼパン－２－カルボキサミド | |
| US7402603B2 (en) | Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination | |
| PE20250009A1 (es) | Composiciones de comprimidos de glp1 | |
| AR035074A1 (es) | Compuestos agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis, su uso en la fabricacion de medicamentos y composiciones farmaceuticas | |
| US20070184109A1 (en) | Compositions comprising triptans and nsaids | |
| JP2007505142A (ja) | 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達 | |
| PE20080522A1 (es) | Derivados de indol como inhibidores de los transportadores de glucosa dependientes de sodio (sglt) | |
| IL145830A0 (en) | Pharmaceutical compositions containing a compound which activates a receptor for glucagon-like peptide-1 | |
| PE20060999A1 (es) | Composiciones farmaceuticas que contienen un diuretico y un bloqueador del receptor de angiotensina ii | |
| PE20231847A1 (es) | Compuestos fosfolipidos y usos de los mismos | |
| AR064636A1 (es) | Nuevos compuestos 621 | |
| EP3291811B1 (en) | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc) | |
| PE20080153A1 (es) | Composicion farmaceutica que comprende un antagonista del peptido relacionado con el gen calcitonina (cgrp) | |
| WO2009099172A1 (ja) | 医薬 | |
| PE20060533A1 (es) | Derivados de dicetopiperazina como antagonistas del receptor de oxitocina | |
| EP1079863A1 (en) | Use of a cox-2 inhibitor and a nk-1 receptor antagonist for treating inflammation | |
| RU2025121729A (ru) | Фармацевтическая композиция агониста гпп для перорального введения | |
| KR20250057860A (ko) | 라이실 옥시다제의 신규한 선택적 저해제 | |
| CO5750042A1 (es) | Composicion farmaceutica que contiene zofenopril y hctz para el tratamiento de la hipertension | |
| AR132834A1 (es) | Composiciones secadas por pulverización que comprenden moduladores del receptor adrenérgico | |
| HK40041640A (en) | Pharmaceutical dosage form which can be administered orally and has modified release | |
| EA200970045A1 (ru) | Фармацевтическая композиция для перорального введения плохо растворимого в воде активного вещества | |
| AR061540A1 (es) | Composicion farmaceutica oral mejorada de un agente activo escasamente soluble en agua | |
| ZA200509860B (en) | Composition comprising triptans and NSAIDS |